Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1499174 | 0.78 | CA1 (0.42) | KDM4EALDH1A1HSD17B10 | |
| Acetonitrile SCHEMBL28216983 | 0.69 | KDM4E (0.38) | KDM4E | |
| SCHEMBL28568831 | 0.69 | KMT2A (0.63) | PDE4DKDM4EALDH1A1 | |
| Hydrogen Peroxide SCHEMBL29022846 | 0.69 | CA1 (0.45) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL28010915 | 0.68 | ALDH1A1 (0.50) | ALDH1A1HSD17B10 | |
| SCHEMBL4350819 | 0.68 | HSD17B10 (0.47) | LIPEPDE4DKDM4EALDH1A1HSD17B10 | |
| SCHEMBL6827899 | 0.67 | HCAR2 (0.39) | HCAR2PDE4DP2RX7 | |
| SCHEMBL10956372 | 0.66 | ALDH1A1 (0.37) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL317719 | 0.66 | CA1 (0.46) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL111872 | 0.66 | HCAR2 (0.46) | HCAR2P2RX7KDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220365-A1 | Cell adhesion-inhibiting antiinflammatory compounds | STEWART ANDREW O (US) | 2003-11-27 | — | — | US | disclosed |
| US-6579882-B2 | Thieno(2,3-d)pyrimidine derivatives | ABBOTT LABORATORIES | 2003-06-17 | — | — | US | disclosed |
| EP-1181296-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2002-02-27 | — | — | EP | disclosed |
| US-20010020030-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ABBVIE INC. | 2001-09-06 | — | — | US | disclosed |
| US-6232320-B1 | THIENO(2,3-C)PYRIDINE AND 5H-THIENO(2,3-C)PYRAN DERIATIVES | ABBOTT LABORATORIES | 2001-05-15 | — | — | US | disclosed |
| EP-1090009-A2 | CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-2000075145-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-12-14 | — | — | WO | disclosed |
| WO-1999062908-A2 | CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020030-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ICAM1, VCAM1, EPCAM | LIPE 3735/4885HCAR2 637/4885PDE4D 3495/4885 |
| US-20030220365-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ICAM1, VCAM1, EPCAM | LIPE 3735/4885HCAR2 637/4885PDE4D 3495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.